A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-1)
A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects With Acromegaly Treated With Long-acting Somatostatin Receptor Ligands (PATHFNDR-1)
Sponsor: Crinetics Pharmaceuticals Inc.
Listed as NCT04837040, this PHASE3 trial focuses on Acromegaly and remains ongoing. Sponsored by Crinetics Pharmaceuticals Inc., it has been updated 18 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
18 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE3
-
Feb 2026 — Mar 2026 [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE3
-
Jul 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Jul 2025 [monthly]
Active Not Recruiting PHASE3
▶ Show 13 earlier versions
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE3
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Oct 2023 — Apr 2024 [monthly]
Active Not Recruiting PHASE3
-
Dec 2022 — Oct 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
May 2022 — Jul 2022 [monthly]
Recruiting PHASE3
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE3
-
Feb 2022 — Apr 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Feb 2022 [monthly]
Recruiting PHASE3
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE3
-
May 2021 — Sep 2021 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Crinetics Pharmaceuticals Inc.
For direct contact, visit the study record on ClinicalTrials.gov .